News & Updates
– AMX-818, an HER2-targeted T cell engager (TCE), is the lead program in Amunix’s XPAT® (XTENylated Protease-Activated TCE) platform designed to improve the therapeutic index of TCEs for the treatment of patients with solid tumors. – The collective preclinical data indicate that AMX-818 is effective in driving anti-tumor responses, yet has significantly lower toxicity than its unmasked HER2 TCE counterpart. This…
Read More
– Lead oral PRMT5 inhibitors PRT543 and PRT811 demonstrate favorable safety profile, evidence of preliminary clinical activity including durable responses and high levels of target inhibition of PRMT5 in Phase 1 dose escalation in unselected patients – – CDK9 inhibitor PRT2527 demonstrates strong efficacy in hematological malignancies and solid tumor models with MYC dysregulation in preclinical studies…
Read More
Excerpt from the Press Release: MARLBOROUGH, Mass., Oct. 7, 2021 /PRNewswire/ — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today presented new data with PH-894, Phio’s self-delivering RNAi compound targeting the bromodomain-containing protein 4 (BRD4) at the AACR-NCI-EORTC Virtual International Conference on Molecular…
Read More
Preclinical data demonstrate that XMT-2056 activates the STING pathway in a target-dependent manner in both tumor cells and tumor-resident immune cells and is significantly more efficacious in head-to-head studies than trastuzumab-TLR7/8 agonist ADC and small-molecule systemically-administered STING agonist benchmarks XMT-2056 targets a novel epitope of HER2 with differentiated binding from trastuzumab and pertuzumab, potentially allowing…
Read More
Excerpt from the Press Release: LEXINGTON, Mass., Oct. 7, 2021 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced two poster presentations with new preclinical data for CA-4948, a first-in-class small molecule IRAK4 inhibitor, at the AACR-NCI-EORTC Virtual Conference on Molecular Targets and Cancer Therapeutics.…
Read More
Confirmed Objective Response Rate of 48 Percent in Patients with NTRK+ TKI-Pretreated Advanced Solid Tumors Confirmed Objective Response Rate of 62 Percent in NTRK+ TKI-Pretreated Advanced Solid Tumor Patients with Solvent Front Mutations Breakthrough Therapy Designation Recently Granted in Patients with NTRK+ Advanced Solid Tumors Who Have Progressed Following Treatment with 1 or 2 Prior TKIs Confirmed…
Read More
• Demonstrated statistically significant anti-tumor activity and inhibited proliferative and stem-cell signaling pathways • Induced beneficial changes in the tumor microenvironment by increasing production of proteins involved in interferon- α and interferon- γ pathways • Demonstrated statistically significant increases in survival when combined with carboplatin and everolimus (mTOR inhibitor) Excerpt from the Press Release: SAN…
Read More
Data published in bioRxiv confirmed previous findings suggesting mucosal vaccines could reduce transmission of airborne viruses such as COVID-19 and flu more than injectable vaccinesStudy suggests mucosal vaccines may protect not only vaccinated, but also unvaccinated animals Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Oct. 7, 2021 /PRNewswire/ — A Duke University-led study published in bioRxiv showed that Vaxart,…
Read More
Program delivered on smartphone is based on core principles of cognitive behavioral therapy, with focus on behavioral activation Trial results demonstrate clinically meaningful reduction in depression symptoms Completing SparkRx as recommended results in statistically significant reduction in symptoms compared to control Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–Today, Limbix, a prescription digital therapeutic company developing…
Read More
Excerpt from the Press Release: BENGALURU, Oct 6 (Reuters) – Bharat Biotech said on Wednesday it had submitted data from its COVID-19 vaccine trial in children aged 2 to 18 years to India’s drug regulator, becoming the country’s first company to have tested its shot in very young children. The South Asian country is turning…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?